Scientists at the National Cancer Institute (NCI) developed a potent chimeric antigen receptor (CAR) targeting glypican-3 (GPC3). GPC3 is a cell surface proteoglycan preferentially expressed on Hepatocellular Carcinoma (HCC). The specific HN3 nanobody-IgG4H-CD28TM CAR included in this invention was much more potent both in in vitro cell models and in vivo mouse models. The NCI seeks licensing and/or co-development research collaborations for further development of the anti-GPC3 CAR to treat liver cancer.
The National Cancer Institute (NCI) seeks licensees for a collection of T-cell receptors (TCRs) that specifically target the CD20 antigen expressed in B-lymphoid malignancies such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The TCRs are being developed as therapeutics for the treatment of lymphomas and leukemias.
Researchers at the National Cancer Institute (NCI) have isolated a panel of anti-CD276 (also called B7-H3) single domain antibodies (also known as nanobodies). These antibodies have a high affinity for CD276-positive tumor cells and have great potential for diagnostic and therapeutic technologies against solid tumors. The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies.
Chimeric Antigen Receptor T cell (CAR-T) therapies that specifically target Signaling Lymphocyte Activation Molecule F7 (SLAMF7) are strong therapeutic candidates for patients with Multiple Myeloma (MM). SLAMF7 is highly expressed on the malignant plasma cells that constitute MM. The expression of SLAMF7 by MM cells and lack of expression on nonhematologic cells makes SLAMF7 an attractive therapeutic target for MM. Researchers at the National Cancer Institute (NCI) have invented anti- SLAMF7 CAR constructs that allow genetically-modified T cells to express both the anti-SLAMF7 antibody and a suicide gene that allows T cells to specifically recognize and kill SLAMF7-expressing cells as well as allow for on-demand and reliable elimination of anti-SLAMF7 CAR T cells. NCI seeks licensing and/or co-development partners for this invention.
Researchers at the National Cancer Institute (NCI) have developed a method by which memory T cells can be generated from other T cell populations using overexpression of the transcription factor c-Myb. Importantly, these reprogrammed memory T cells show increased proliferative and survival capacity. This strategy could also potentially generate anti-tumor T cells with improved viability and therapeutic efficacy for adoptive ACT. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.
Researchers at the National Cancer Institute (NCI) seek research & co-development and/or licensees for a novel, ex vivo method by which stem cell-like memory T cells (Tscm) can be generated by stimulating naïve T cells in the presence of inhibitors of GSK-3beta, which are capable of activating the Wnt pathway. These Tscm cells, generated using GSK-3beta inhibitors, display enhanced survival and proliferation upon transfer, have multipotent capacity to generate all memory and effector T cell subsets, and show increased anti-tumor activity in a humanized mouse tumor model.
The thymus is the only organ capable of producing conventional, mature T cells; a crucial part of the adaptive immune system. However, its efficiency and function are progressively reduced as we age, leading to a compromised immune system in the elderly. Moreover, production of T cells with specific receptors is an important concern for cancer immunotherapy. Current in vitro methods produce immature T cells that are not useful for therapy. Researchers at the National Cancer Institute (NCI) have generated an autologous thymic organoid from human pluripotent stem cells to address this problem. The organoid can be used to develop clinical applications such as production of autologous T and natural killer T (NKT) cells and reconstitution of the adaptive immune system. NCI is seeking licensees for the thymic organoid and the method of its generation to be used in a variety of clinical applications.
Multi-potential hematopoietic progenitor cells (HPC) can differentiate into any class of blood cells, and are highly useful in regenerative medicine, immunology, and cancer immunotherapy. Current methods to generate HPCs are limited either due to the use of animal products, or the high cost and low efficiency of animal product free systems. Researchers at the National Cancer Institute (NCI) have developed a protocol to prepare HPCs from human induced pluripotent stem cells (hiPSC), using human mesenchymal stem cells (hMSC) in a three-dimensional (3D) co-culture condition. Thus, they are able to generate HPCs in a fully human, autologous system, which can be used to further generate immune cells for therapy. This protocol is adaptable to mass production by bioreactors. NCI seeks licensees for these methods of generating HPCs in a 3D co-culture with hMSCs to be used in a variety of applications such as treatment of blood disorders, regenerative medicine, and antibody production.
T-cells capable of reacting to mutations in cancer patients have potential use as therapeutics. Identifying and isolating these cells from patients is a crucial step in developing these treatments. Researchers at the National Cancer Institute (NCI) have developed a novel method of isolating mutation-reactive T-cells from a patient’s peripheral blood lymphocytes (PBL). The NCI, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this method of isolating mutation-reactive T-cells from peripheral blood.
Metastatic thyroid cancer can be resistant to current treatment options such as radioactive iodine therapy. Targeting thyroglobulin, a thyroid-specific antigen, as part of an adoptive cell therapy approach will allow for new therapeutic possibilities. Researchers at the National Cancer Institute (NCI) seek licensing and/or co-development research collaborations for novel T-cell receptors for the treatment of metastatic thyroid cancer.
Pluripotent stem cells are a promising source of T cells for a variety of clinical applications. However, current in vitro methods of T cell differentiation result in the generation of cells with aberrant phenotypes. Researchers at the National Cancer Institute (NCI) have now developed methodology for generating induced pluripotent stem cell thymic emigrants (iTE). Antigen-specific CD8αβ+ iTEs exhibited functional properties in vitro that were almost indistinguishable from natural naïve CD8αβ+ T cells, including vigorous expansion and robust anti-tumor activity. iTEs recapitulated many of the transcriptional programs of naïve T cells in vivo and revealed a striking capacity for engraftment, memory formation, and efficient tumor destruction. The NCI seeks licensing and/or co-development research collaborations for this invention.
Scientists at the National Cancer Institute (NCI) have developed SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a computational precision-oncology framework harnessing genetic interactions to improve treatment options for cancer patients. NCI seeks collaborators or licensees to advance the development of this technology into precision diagnostics.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development and commercialization of small molecule inhibitors of the Eph receptor tyrosine kinase for Eph growth-dependent solid tumors such as colorectal cancer.
Scientists at the National Cancer Institute (NCI) have discovered a bacterial exonuclease VII (ExoVII) inhibitor that increases the potency of widely used quinolone antibiotics targeting prokaryotic type IIA topoisomerases. NCI seeks research co-development partners and/or licensees for the development of ExoVII inhibitors as new antibiotic adjuvants to boost the efficacy of quinolone antibiotics and/or restore the susceptibility of resistant bacteria.
Chimeric Antigen Receptor T cell (CAR-T) therapies that specifically target B-cell maturation antigen (BCMA) are strong therapeutic candidates for patients with plasma cell malignancy diseases such as, multiple myeloma (MM), as well as for patients with Hodgkin’s lymphoma. BCMA is a cell surface protein preferentially expressed on a subset of B cells and mature plasma cells, but not on other cells in the body. The limited expression of BCMA on B and plasma cells makes BCMA an attractive therapeutic target for B cell and plasma cell malignancy diseases. The 12 anti-BCMA CARs described are fully human CARS and have the potential to treat patients with various plasma cell and B cell malignancy diseases.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for mesothelin targeting Recombinant Immunotoxins (RITs). These RITs have been engineered by site specific modification with polyethylene glycol (PEG) to have an increased serum half-life, while maintaining high cytotoxicity and have greatly improved anti-tumor activity.
The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of cyclic peptides or peptidomimetic molecules as potential non-hormonal contraceptives for males. The cyclic peptides disrupt spermatogenesis by inhibiting the phosphorylation of GRTH/DDX25 (gonadotropin-regulated testicular helicase).
Researchers at the National Cancer Institute (NCI) developed a novel mouse for the detection of TGF-ß signaling. This mouse provides the opportunity to study TGF-ß signaling in vivo and may be a useful model for preclinical pharmacology studies. The NCI seeks licensees for the TGF-ß reporter mouse.